Last updated on: 27/08/2013
Name of organisation
1) Department/Research group
2) Organisation/affiliationConsorzio Mario Negri Sud
Short Name in the inventoryCMNS
Administrative Contact
Title Ms
Last name Cinque
First name Serena
Address line 1via Nazionale 8/A
Address line 2
Address line 3
CitySanta Maria Imbaro
Postcode66030
CountryItaly
Phone number (incl. country code)390872570249
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Romero
First name Marilena
Address line 1via Nazionale 8/A
Address line 2
Address line 3
CitySanta Maria Imbaro
Postcode
CountryItaly
Phone number (incl. country code)390872570255
Alternative phone number
Fax number (incl. country code)
Alternative Scientific Contact
Title Dr
Last name Anecchino
First name Caterina
Address line 1via Nazionale 8/A
Address line 2
Address line 3
CitySanta Maria Imbaro
Postcode
CountryItaly
Phone number (incl. country code)390872570302
Alternative phone number
Fax number (incl. country code)
2. Description
The Consorzio Mario Negri Sud (CMNS) is a non-profit organization for biomedical and pharmacological research.
The CMNS was founded in 1987 as a consortium between the Mario Negri Institute in Milan and the Chieti Province authority, later joined by the Abruzzo Region authority. Scientific activities operatively began on September 1st 1987. Since then, CMNS has given a significant contribution to the advancement of research aimed at the prevention and cure of human diseases. Based on a core of senior staff of around 80 scientists, the CMNS is also dedicated to training of predoctoral and postdoctoral fellows, including an International PhD Programme.
Research at the CMNS covers four main areas of interest: fundamental and translational research; clinical pharmacology and epidemiology (applied to cardiovascular diseases, diabetes and oncology, cognitive and behavioural disturbances of old age, health services, and care of patients); environmental sciences and citizenship and welfare
3. Category
Charity or non-profit organisation
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
No
Statistician
Yes
No
Clinician
Yes
Yes
Clinical Pharmacologist
Yes
No
Pharmacist
Yes
Yes
Geneticist/Pharmacogeneticist
Yes
No
IT specialist
Yes
No
Ethics expertise
No
Yes
Legal expertise
No
Yes
Regulatory expertise
No
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Endocrine disorders
Geriatrics
Infectious diseases
Malignant disease
Musculoskeletal and joint diseases
Psychiatry
Renal impairment
Respiratory diseases
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
Between 1500 and 14999
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
FileMaker Pro
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Hospital discarge records, prescription databases and vital statistics5
11. Registries established by centre
Drug RegistryNew oncologic drugs under Italian Medicines Agency intensive monitoring system and BRMs in chronic inflammatory rheumatic and bowel diseases
Disease RegistryRare tumors (Abruzzo region), national registry on Multiple Sclerosis; amyotrophic lateral sclerosis (Puglia region)
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
None
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Macchia A, Romero M, D'Ettorre A, Tognoni G, Mariani J. Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. PLoS One 2013;8(5):e62772.
Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368(19):1800-8.
De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307(21):2286-94.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF. Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. Ann Intern Med, 153: 23-33 (2010)
Sichetti D, Bandieri E, Romero M, Di Biagio K, Luppi M, Belfiglio M, Tognoni G, Ripamonti CI; for ECAD Working Group. Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Annals of Oncology 2010; 21 (10): 2088-93
